Comparative studies of the effects of Tabebuia avellanedae bark extract and beta-lapachone on the hematopoietic response of tumour-bearing mice

dc.creatorQueiroz, MLS
dc.creatorValadares, MC
dc.creatorTorello, CO
dc.creatorRamos, AL
dc.creatorOliveira, AB
dc.creatorRocha, FD
dc.creatorArruda, VA
dc.creatorAccorci, WR
dc.date2008
dc.dateMAY 8
dc.date2014-11-16T22:52:17Z
dc.date2015-11-26T17:27:10Z
dc.date2014-11-16T22:52:17Z
dc.date2015-11-26T17:27:10Z
dc.date.accessioned2018-03-29T00:14:19Z
dc.date.available2018-03-29T00:14:19Z
dc.identifierJournal Of Ethnopharmacology. Elsevier Ireland Ltd, v. 117, n. 2, n. 228, n. 235, 2008.
dc.identifier0378-8741
dc.identifierWOS:000256207700005
dc.identifier10.1016/j.jep.2008.01.034
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/56143
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/56143
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/56143
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1284730
dc.descriptionThe effects of Tabebuia avellanedae (TACE), traditionally prescribed in the treatment of cancer, and the naphtoquinone beta-lapachone (beta-lap) on the growth and differentiation of granulocyte and macrophage progenitor cells (CFU-GM) were studied in Ehrlich ascites tumour-bearing mice. Myelosuppression concomitant with increases in spleen CFU-GM and in serum colony-stimulating activity (CSA) were observed in these animals. Treatment with TACE (30-500 mg/kg) and beta-lap (1-5 mg/kg) reversed these effects in a dose-dependent manner. The optimal biologically active doses of 120 mg/kg TACE and 1 mg/kg beta-lap prolonged life span of tumour-bearing mice, both producing the same rate of extension in the duration of survival. Toxic manifestations were produced by the higher doses of beta-lap in normal and tumour-bearing mice. In spite of similarities between treatments, TACE concentrations used to treat the animals presented no traces of beta-lap, as measured by TLC and HPLC analyses. Our findings suggest that the antitumour effect of TACE and beta-lap, acting synergistically with other factors, such as specific cytokines, may result from enhanced macrophage activation against tumour cells. In addition, it is clear from our results that hematopoietic disorders produced by tumours are an important pathological condition that must be considered in drug development. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
dc.description117
dc.description2
dc.description228
dc.description235
dc.languageen
dc.publisherElsevier Ireland Ltd
dc.publisherClare
dc.publisherIrlanda
dc.relationJournal Of Ethnopharmacology
dc.relationJ. Ethnopharmacol.
dc.rightsfechado
dc.rightshttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.sourceWeb of Science
dc.subjectTabebuia avellanedae
dc.subjectbeta-lapachone
dc.subjectmyelopoiesis
dc.subjectextramedular hematopoiesis
dc.subjectcolony-stimulating activity (CSA)
dc.subjectantitumoural efficacy
dc.subjectEhrlich Ascites Tumor
dc.subjectCancer Cells
dc.subjectCfu-c
dc.subjectMacrophages
dc.subjectCytotoxicity
dc.subjectDichloride
dc.subjectApoptosis
dc.subjectTnf
dc.titleComparative studies of the effects of Tabebuia avellanedae bark extract and beta-lapachone on the hematopoietic response of tumour-bearing mice
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución